omniture
logo
Search
南京药捷安康生物科技有限公司 Nanjing TransThera Biosciences Ltd.
Media Room

Latest News

rss

【2024 AACR Late Breaking Research】TransThera announces clinical data of tinengotinib to treat patients with advanced solid tumors harboring actionable FGFR1-3 alterations

NANJING, China and GAITHURSBURG, Md., April 12, 2024 /PRNewswire/ -- TransThera Sciences, a clinica...

2024-04-12 21:00 1600

TransThera Announced Global Phase 3 Clinical Trial for Cholangiocarcinoma Authorized in the European Union and Orphan Drug Designation for Tinengotinib to Treat Biliary Tract Cancer Granted by European Medicines Agency

NANJING, China and GAITHURSBURG, Md., March 8, 2024 /PRNewswire/ -- TransThera, a clinical-stage bi...

2024-03-08 21:00 2440

TransThera initiates IND-Enabling studies for TT-02332, a novel, highly potent and CNS-penetrating NLRP3 inhibitor

NANJING, China and GAITHURSBURG, Md., Feb. 26, 2024 /PRNewswire/ -- TransThera, a clinical-stage bi...

2024-02-26 21:00 902

TransThera Announces the Global Multicenter Phase 3 Clinical Trial Completed First Patient Dosing in the US Evaluating Tinengotinib in FGFRi Relapsed/Refractory Patients with Cholangiocarcinoma

NANJING, China and GAITHURSBURG, Md., Dec. 21, 2023 /PRNewswire/ -- TransThera, a clinical-stage bi...

2023-12-21 21:45 1248

2023 SABCS - TransThera announces an oral presentation of tinengotinib clinical data in breast cancer

NANJING, China, Dec. 7, 2023 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage b...

2023-12-07 21:00 1190

TransThera announces two oral presentations of tinengotinib clinical data at 2023 ESMO and SABCS annual meetings

NANJING, China, Oct. 9, 2023 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage b...

2023-10-09 21:00 1319

TransThera Announces that the IND Application of TT-01488, a Non-covalent Reversible BTK Inhibitor, for the Treatment of B-Cell Lymphomas has been Approved by the FDA in the US and Officially Accepted by the NMPA in China

NANJING, China, Feb. 18, 2022 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. ("TransThera") an...

2022-02-18 22:00 3960

TransThera Receives Fast Track Designation from FDA for its Core Product TT-00420 to Treat Cholangiocarcinoma

NANJING, China, Nov. 3, 2021 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage b...

2021-11-03 22:00 1396

TransThera announces collaboration with Roche to evaluate TT-00420 as part of a novel combination to treat GI cancers in China

NANJING, China, May 26, 2021 /PRNewswire/ -- TransThera Biosciences Co. Ltd. ( "TransThera" ), a cl...

2021-05-26 21:00 1279

Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration

TOKYO and NANJING, China, Dec. 18, 2020 /PRNewswire/ -- Teijin Pharma Limited

2020-12-18 23:30 3245

TransThera Biosciences Announces IND Approval from FDA for Clinical Studies of TT-00920 to Treat Chronic Heart Failure

NANJING, China, Dec. 16, 2019 /PRNewswire/ -- TransThera Biosciences Co. Ltd, a clinical-stage biot...

2019-12-17 08:00 1261

TransThera Biosciences Lead Product TT-00420 Granted Orphan Drug Designation from FDA to Treat Cholangiocarcinoma

NANJING, China, Nov. 7, 2019 /PRNewswire/ -- TransThera Biosciences Co. Ltd, announced today that c...

2019-11-07 20:08 1045